Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Biosimilars
 More »

THIS KEYWORD IS SPONSORED BY:

  • Biosimilars Asia
    Shanghai CHINA www.biosimilarsasia.com
    5-20-2013
  • Heightened Characterization of Therapeutic mAbs Using a Novel...
    LC-MS analysis How this enzyme can be used for rapid comparability studies of biosimilars vs. innovator compounds How these enzyme systems can be used to screen production ...
    5-15-2013
  • Improving Proteomics Approaches
    ... trend toward biotherapeutics and the need for rapid analysis and characterization of putative products. "Related are biotech patent expirations and the development of biosimilars." ...
    5-15-2013
  • Oncobiologics Finds Partner to Launch Biosimilars in U.S., China
    for the Chinese market four biosimilars being developed by U.S.-based ... partnership for launching the biosimilars in more than 30 developed countries, ...
    5-8-2013
  • BIO Celebrates 20th Anniversary
    Tuesday, April 23 How IP Issues Impact Innovations in Biomarker Diagnostics & Personalized Medicine: 10:15 a.m. - 11:30 a.m. Monday, April 22 Global Regulation of Biosimilars: ...
    4-22-2013
  • Biosimilars: 10 Drugs to Watch
    the FDA continues to ponder draft guidances for how the agency will evaluate biosimilars. ... How should interchangeability of biosimilars to innovator products be determined? How ...
    4-22-2013
  • Pfenex and Agila Biotech Target Biosimilars
    Liang, M.D., Ph.D., CEO at Pfenex. "Biosimilars are and will play an increasingly ... Markets and Markets estimates that the global biosimilars market will total $19.4 billion ...
    4-16-2013
  • Single-Use Bioreactor Roundup
    ... In the future, we expect to see more of these advanced control approaches in support of QbD-driven production approaches. Moreover, biosimilars or biobetters will require a lean ...
    4-15-2013
  • Poland Invests in Biotech Infrastructure
    Biosimilars or Biobetters? Polpharma Biologics was set up at the Gdansk Science and ... affordable biosimilars, Polpharma decided to set up a biologics division at Gdansk. ...
    4-15-2013
  • Obama Budget: More NIH Grants, Higher FDA User Fees
    ... No generic or biosimilar fees were collected in FY 2012. Those fees, FDA says, will help pay for it to adopt a pathway for approving biosimilars and biologic drugs. Obama's budget ...
    4-11-2013
  • Electronics Giants Set Sights on Biotech
    with Merck & Co. to create "multiple pre-specified" undisclosed biosimilars. The collaboration follows separate biosimilars failures by Samsung and Merck in recent years. ...
    4-1-2013
  • Steric Exclusion Chromatography
    ... Most of the characterization work to date has been done with a Trastuzumab biosimilar produced in CHO cells at about 2 g/L, but Bevacizumab and Adalimumab biosimilars give ...
    3-15-2013
  • Biosimilars: Not So Far So Fast
    Until very recently, biosimilars were expected to become an increasingly large part of the ... reduced "momentum" on the part of some key players on track to produce biosimilars. ...
    3-15-2013
  • Electronics Giant Samsung Makes First Big Biotech Play
    and Biogen Idec to focus on biosimilars, has a R&D center based in Song-do Incheon, Korea. ... companies well to increase access to biosimilars to improve human health," said Rich ...
    2-20-2013
  • Optimizing the Quality and Accuracy of Biopharmaceutical Analysis...
    Biopharmaceuticals and biosimilars are highly complex, heterogeneous drugs that require a high level of analytical scrutiny. Their analysis often requires time-consuming ...
    2-19-2013

  • Journal Articles

  • The Emergence of Biosimilar Insulin Preparations-A Cause for...
    David Owens, Andrea Schmidt, Wolfgang Landgraf, Reinhard G. Bretzel, Martin K Kuhlmann
    Diabetes Technology & Therapeutics
    are, or shortly will be, off-patent, thereby becoming the focus of pharmaceutical companies interested in attempting to manufacture "copies" commonly described as biosimilars. ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll